Table 3.

Scenarios of assignments of best overall response using iRECIST

	Timepoint response 1	Timepoint response 2	Timepoint response 3	Timepoint response 4	Timepoint response 5	iBOR
Example 1	iCR	iCR, iPR, iUPD, or NE	iCR, iPR, iUPD, or NE	iUPD	iCPD	iCR
Example 2	iUPD	iPR, iSD, or NE	iCR	iCR, iUPD, or NE	iCR, iPR, iSD, iUPD, iCPD, or NE	iCR
Example 3	iUPD	iPR	iPR, iSD, iUPD, or NE	iPR, iSD, iUPD, NE, or iCPD	iPR, iSD, iUPD, NE, or iCPD	iPR
Example 4	iUPD	iSD or NE	iPR	iPR, iSD, iUPD, or NE	iPR, iSD, iUPD, iCPD, or NE	iPR
Example 5	iUPD	iSD	iSD, iUPD, or NE	iSD, iUPD, iCPD, or NE	iSD, iUPD, iCPD, or NE	iSD
Example 6	iUPD	iCPD	Any	Any	Any	iCPD
Example 7	iUPD	iUPD (no iCPD)	iCPD	Any	Any	iCPD
Example 8	iUPD	NE	NE	NE	NE	iUPD

Eight examples are presented for patients with target disease at baseline, but many more scenarios exist following the same principles. Table assumes a randomised study in which confirmation of complete response or partial response is not required. For patients with non-target disease only at baseline, only iCR or non-complete response or non-progression of disease can be assigned at each timepoint (not shown in the table for ease of presentation). “i” indicates immune responses assigned using iRECIST. iBOR=best overall response. iCR=complete response. iPR=partial response. NE=not evaluable. iUPD=unconfirmed progression. iCPD=confirmed progression. iSD=stable disease. RECIST=Response Evaluation Criteria in Solid Tumours.